A biosensor capable of counting the blood cells electrically using only a drop of blood is being demonstrated by researchers from the University of Illinois at Urbana-Champaign (UIUC). The blood cell count is among the most ubiquitous diagnostic tests in primary health care.
The gold standard routinely used in hospitals and testing laboratories is a hematology analyzer, which is large and expensive equipment, and requires trained technicians and physical sample transportation. It slows turn-around time, limits throughput in hospitals, and limits accessibility in resource-limited settings. Bashir and his team have developed a biosensor to count red blood cell, platelet, and white blood cell counts, and its 3-part differential at the point-of-care while using only 11 microL of blood.
Better Understanding of Cancer-Spreading Enzymes Secreted by White Blood Cells
The enzyme MMP7 signals to cancer cells to become more aggressive when the enzyme cuts off specific proteins as it binds to those cancer cells.
Advertisement
‘Scientists from the University of Illinois develop a biosensor capable of counting the blood cells electrically using only a drop of blood.’
Tweet it Now
The microfluidic device can electrically count the different types of blood cells based on their size and membrane properties. To count leukocyte and its differentials, red blood cells are selectively lysed and the remaining white blood cells were individually counted. The specific cells like neutrophils were counted using multi-frequency analysis, which probe the membrane properties of the cells. However, for red blood cells and platelets, 1 microL of whole blood is diluted with PBS on-chip and the cells are counted electrically. The total time for measurement is under 20 minutes. The report appears in the December 2015 issue of the journal TECHNOLOGY.
"Our biosensor exhibits the potential to improve patient care in a spectrum of settings. One of the compelling is in resource-limited settings where laboratory tests are often inaccessible due to cost, poor prevalence of laboratory facilities, and the difficulty of follow-up upon receiving results that take days to process," says Professor Rashid Bashir of the University of Illinois at Urbana-Champaign and Principal Investigator on the paper.
![Impact of High-Fat Diet on Red Blood Cells Promotes Cardiovascular Diseases]( "Impact of High-Fat Diet on Red Blood Cells Promotes Cardiovascular Diseases")
Evidence is emerging that RBCs play an important role in atherosclerosis development, binding pro-inflammatory proteins that cause dysfunction in the endothelium.
"There exists a huge potential to translate our biosensor commercially for blood cell counts applications," says Umer Hassan, Ph.D., the lead author on this paper. "The translation of our technology will result in minimal to no experience requirement for device operation. Even, patients can perform the test at the comfort of their home and share the results with their primary care physicians via electronic means too." "The technology is scalable and in future, we plan to apply it to many other potential applications in the areas of animal diagnostics, blood transfusion analysis, ER/ICU applications and blood cell counting for chemotherapy management" says Professor Bashir. The clinical trials of the biosensor are done in collaboration with Carle Foundation Hospital, Urbana, IL.
The team from UIUC is working now to further develop a first portable prototype of the cell counter. "The cartridges will be disposable and the size of a credit card. The base unit or the reader will be portable and possibly hand-held. Our technology has the potential to reduce the cost of the test to less than $10 as compared to $100 or more currently charged," says Umer.
Source: Eurekalert
Impact of High-Fat Diet on Red Blood Cells Promotes Cardiovascular Diseases
Evidence is emerging that RBCs play an important role in atherosclerosis development, binding pro-inflammatory proteins that cause dysfunction in the endothelium.
Advertisement
"There exists a huge potential to translate our biosensor commercially for blood cell counts applications," says Umer Hassan, Ph.D., the lead author on this paper. "The translation of our technology will result in minimal to no experience requirement for device operation. Even, patients can perform the test at the comfort of their home and share the results with their primary care physicians via electronic means too." "The technology is scalable and in future, we plan to apply it to many other potential applications in the areas of animal diagnostics, blood transfusion analysis, ER/ICU applications and blood cell counting for chemotherapy management" says Professor Bashir. The clinical trials of the biosensor are done in collaboration with Carle Foundation Hospital, Urbana, IL.
The team from UIUC is working now to further develop a first portable prototype of the cell counter. "The cartridges will be disposable and the size of a credit card. The base unit or the reader will be portable and possibly hand-held. Our technology has the potential to reduce the cost of the test to less than $10 as compared to $100 or more currently charged," says Umer.
Source: Eurekalert
Here's How Malarial Parasite Finds Its Way Into Our Red Blood Cells
There is a protein on the surface of human red blood cells that serves as an essential entry point for invasion by the malaria parasite.
Advertisement
 Researchers Discover Genomic Switches of Blood Cells That Regulate the Immune SystemA team of researchers at the National Institutes of Health has discovered the genomic switches of a blood cell key to regulating the human immune system. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Link between advanced paternal age and higher risks for reproductive and offspring medical problems has been discovered.
Can gene astrology predict disease risk? Yes, your genes can determine your future health and disease risk.
Injury to the white matter explains why football players are at an increased risk for cognitive and behavioral problems later in life.
Located at the South Col, the rocky area between Mount Everest and Lhotse serves as the final campsite for climbers as well as a frozen legacy of hardy microbes.
The new finding is found to be valuable for screening specific medications and treatment against Giardia and other protozoan parasites.